Abstract
Metabolic syndrome (MetS) is a cluster of the most dangerous risk factors for type 2 diabetes mellitus and cardiovascular disease. The 1131T/C polymorphism of the apolipoprotein A5 (ApoA5) gene is associated with hypertriglyceridemia and correlates with impaired glucose homeostasis. These observations prompted us to explore the frequency of ApoA5 1131T/C polymorphism among patients with MetS as to assess its effects on lipid metabolism and insulin resistance. The study was conducted on 90 subjects divided into two groups: 60 MetS patients and 30 healthy controls. Fasting glucose, lipid profile, C-peptide (ELISA), and ApoA5 1131T/C polymorphism (PCR-RFLP) were done to all participants. CC genotype of ApoA5 gene was present only in MetS group compared to controls with a frequency of 13.3 vs. 0 % (P = 0.011), while the wild genotype (TT) was more frequent among the controls (86.7 vs. 56.7 %, P = 0.011). The mutant genotypes (TC, CC) were associated with higher risk for MetS (OR 4.97, 95 % CI = 1.5–16). The C allele was significantly increased in cases compared to controls (28.3 vs. 6.7 %, P = 0.001) and was associated with increased risk of MetS (OR = 5.535, 95 % CI = 1.8–16.4). Cholesterol, triglycerides, glucose levels, and modified HOMA-IR showed significantly higher values among TC/CC genotype carriers compared to TT genotype carriers, while HDL showed significantly lower values in the TC/CC genotype carriers compared to TT genotype carriers among MetS patients. Our findings show that ApoA5 gene 1131T/C polymorphism is associated with higher risk for MetS, and that the C allele carriers are more susceptible to dyslipidemia and insulin resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aboul Ella NA, Shehab DI, Ismail MA, Maksoud AA (2010) Prevalence of metabolic syndrome and insulin resistance among Egyptian adolescents 10 to 18 years of age. Clin lipidol 4(3):185–195
Alberti KG, Zimmet PZ (2008) Should we dump the metabolic syndrome? No. BMJ 336:641
Ashby JP, Frier BM (1981) Circulating C peptide: measurement and clinical application. Ann Clin Biochem 18(Pt 3):125–130
Cameron AJ, Shaw JE, Zimmet PZ (2004) The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33(2):351–375
Church TS, Thompson AM, Katzmarzyk PT, et al (2009) Metabolic syndrome and diabetes, alone and in combination, as predictors of cardiovascular disease mortality among men. Diabetes Care 32(7):1289–1294
Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27(10):2444–2449
Fruchart JC, Sacks F, Hermans MP et al (2008) The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102(10 Suppl):1K–34K
Grallert H, Sedlmeier EM, Huth C et al (2007) APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res 48:2614–2621
Groenendijk M, De Bruin TW, Dallinga-Thie GM (2001) Two polymorphisms in the Apo A-IV gene and familial combined hyperlipidemia. Atherosclerosis 158(2):369–376
Grundy SM, Brewer HB, Cleeman JI et al (2004) Definition of metabolic syndrome: report of the National, Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438
Hsu LA, Ko YL, Chang CJ et al (2006) Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 185:143–149
Hsu LA, Ko YL, Chang CJ et al (2008) Apolipoprotein A5 gene 1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan. Clin Chem Lab Med 46:1714–1719
Ishihara M, Kujiraoka T, Iwasaki T et al (2005) A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 46:2015–2022
Joy T, Hegele RA (2008) Genetics of metabolic syndrome: is there a role for phenomics? Curr Atheroscler Rep 10:201–208
Kao JT, Wen HC, Chien KL et al (2003) A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 12:2533–2539
Kisfali P, Mohas M, Maasz A et al (2010) Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome. Nutr Metab Cardiovasc Dis 20:505–511
Komurcu-Bayrak E, Onat A, Poda M et al (2008) Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T > C and c.56C > G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults. Clin Chem Lab Med 46:778–784
Li X, Zhou ZG, Qi HY et al (2004) Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function. Zhonghua Yi Xue Yi Chuan Xue ZaZhi (Chinese) 29(4):419–423
Maasz A, Kisfali P, Horvatovich K et al (2007) Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res 13:243–247
Ng MC, So WY, Lam VK et al (2004) Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 53:2676–2683
Nowak M, Helleboid-Chapman A, Jakel H et al (2005) Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 25:1537–1548
Ong KL, Jiang CQ, Liu B, Jin YL, Tso A, Tam S, Wong KS et al (2011) Association of a genetic variant in the apolipoprotein A5 gene with the metabolic syndrome in Chinese. Clin Endocrinol 74:206–213
Pennacchio LA, Olivier M, Hubacek JA et al (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169–173
Reaven G (2004) The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 33:283–303
Reilly MP, Rader DL (2003) The metabolic syndrome more than the sum of its parts? Circulation 108:1546–1551
Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ et al (2002) Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11:3039–3046
Tang Y, Sun P, Guo D et al (2006) A genetic variant c.553G > T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis 185:433–437
Sarwar N, Sandhu MS (2010) Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Triglyceride- mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375:1634–1639
Weinberg RB, Cook VR, Beckstead JA et al (2003) Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 278:34438–34444
Yamada Y, Kato K, Hibino T et al (2007) Prediction of genetic risk for metabolic syndrome. Atherosclerosis 191:298–304
Yan SK, Cheng XQ, Song YH, Xiao XH, Bi N, Chen BS (2005) Apolipoprotein A5 gene polymorphism-1131T- > C: association with plasma lipids and type 2 diabetes mellitus with coronary heart disease in Chinese. Clin Chem Lab Med 6:607–612
Conflicts of interest
The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fathy, M.M., Wahab, A.AA., Tabozada, S. et al. Association of apolipoprotein A5 gene 1131T/C polymorphism with dyslipidemia and insulin resistance in Egyptian patients with metabolic syndrome. Comp Clin Pathol 22, 1245–1250 (2013). https://doi.org/10.1007/s00580-012-1558-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00580-012-1558-7